PTK2 and pachyonychia congenita: As FAK expression and activity levels can vary both at the intertumoral patient level and intratumoral levels within the tumor’s stromal and epithelial compartments (30–32), tailoring treatment regimens depending on individual tumor status could allow for a personalized approach to FAK targeting in PC.